The Arkansas Insurance Department is holding a public hearing this Friday morning on whether it should strike down as unconstitutional the nation’s first state law to address pharmaceutical manufacturer denials of 340B pricing on drugs when they are dispensed by
…Category: State
North Carolina lawmakers are debating whether to grant all 340B covered entities and their contract pharmacies, or only some, protection against discrimination by pharmacy benefit managers.
Last week Thursday, state House and Senate leaders appointed members to a conference committee
…340B covered entities will get none of the $75 million Bristol Myers Squibb is paying California, 27 other states, and the federal government to settle claims it underreported its average manufacturer prices (AMPs) in order to underpay Medicaid drug rebates.
…California’s twice-postponed shift of Medicaid (Medi-Cal) managed care prescription drug benefits to Medi-Cal fee for service (FFS) is back on for Jan. 1, 2022, one year later than originally planned.
A similar high-stakes battle over Medicaid reimbursement for 340B-purchased drugs
…Wisconsin Gov. Tony Evers (D) is pushing for passage of a package of 13 “Less for Rx” bills to control prescription drug costs, including one to eliminate payer and pharmacy benefit manager (PBM) discrimination against certain 340B covered entities.
The
…Sixteen states have passed laws since 2019 addressing pharmacy benefit manager (PBM) discrimination against 340B covered entities, according to a draft summary of state action on the subject circulating among community health center advocates.
Meanwhile, two longtime 340B program policy
…In the last two years, over one-third of all state lawmakers nationwide accepted at least one pharmaceutical industry campaign contribution, news organization STAT reports.
The industry wrote over 10,000 individual checks totaling more than $9 million to “at least 2,467
…Vermont’s legislature has voted to bar pharmacy benefit managers (PBMs) from requiring claims modifiers on 340B-purchased drugs, except for claims paid directly or indirectly by Medicaid.
PBMs also would be unable to restrict 340B contract pharmacies’ access to pharmacy networks
…